 +85256339380       +85259719809        HKSTHL@outlook.com
Home / News / Biological Role and Therapeutic Potential of IDH Mutations in Cancer

Biological Role and Therapeutic Potential of IDH Mutations in Cancer

Views: 2     Author: Site Editor     Publish Time: 2023-02-02      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button
Biological Role and Therapeutic Potential of IDH Mutations in Cancer


Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation. Small-molecule inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clinical and clinical development. In this review, we provide an overview of mutant IDH-targeted therapy and discuss a number of important recent pre-clinical studies using models of IDH-mutant solid tumors.




Contact HL today to boost your 
pharmaceutical business. 
We are ready to assist 24/7.

Quick Links

Product Category

Contact Us
  HKSTHL@outlook.com
  +85259719809
  +85256339380
   808 Kwong Ning Building, Shatin District, Hong Kong
Copyright © 2023 Hong Kong Hongli Import And Export Co.,LTD. All rights reserved.